Xcelerate Inc (QB) (XCRT) Share Price

Nothing like an 80% pop in share price on NO news. And, No volume! Much of the Float (awfully small one at that) is in more patient hands now. Imagine what XCRT/share price will do once we get some news on the good side!

No updates in a while, right along with ZERO dilution? Generating income through the ESN Group. Borgers really put a damper on what they had going on last year. Takes time to clear up all the paperwork involved. So, could be they are working on getting things lined up to move forward.

I sure ain’t going anywhere…regardless of the opines of a couple serious Debbie-Downers😂😂😂😂

No dilution but in the same sentence, phantom sellers drying up?

Total clowns?

These sellers?

Who?

.174 to .013 is dilution?

IMO

Over and over and over again we see there is no dilution here. They update it quire regularly.


So, at some point the sellers dry up and the SP rebounds.

Now we just need some solid updates and we'll be moving north again. jmo


XCRT

Long time no see. What ya think about today's move? +79% to .02756 volume 313k.

Liquidity & capital resources disheartening !

https://www.otcmarkets.com/filing/html?id=17852428&guid=jh0-ke1lnfZnJth

Wonder if shareholders had a choice of a .13 PPS and dilution in the last year or a .013 PPS with no dilution in the last year?

Oh the choices?

I hope the next wave of dilution is like the last one, this time drop 100,000,000 millions shares to a 3rd party then trickle sell them over a year period so dimwits can boast about no dilution in over a year while the PPS continues to tank?

IMO

Benevolence is my nature !

S/S Update this morning. UNCHANGED! It’s now been ~ a year and half since it’s changed. Revenues going up and dilution? Not going up? Market Cap $6 million. Next update she pops. IMO

https://www.otcmarkets.com/stock/XCRT/security

You're being too charitable! $0.174 to $0.0125

So $0.174 to $0.0145 is no dilution. > WOW < !

Bid is now .012? Does Shoddy O'Shea have a rebuttal?

From .13 to .012 yet these clowns over various social media platforms just keeping deflecting the blame on anyone except the part time CEO who has destroyed shareholder value?

Did Mike drop the ball on Affiyasassa?
Hire a convicted felon to run marketing?
Lie about financials?

I wouldn't worry though some silly 3rd party promoter should come along any moment and tell everyone what another buying opportunity this is and how much money they are making while the PPS flies into a death spiral?

IMO

Of course you have no rebuttal.
Just shaking that crystal ball negativity. Baking stuff up per usual.
Nothing of substance.

Always an excuse for Shoddy O'Shea?

From every level .13 to .013 these horrendous 3rd party con artist, vomit up excuses all over social media for Mr. "WERE DONE"?

Is that how mike could walk away from Xcelerate?

The same way he walks out of depositions saying we're done?

Is bankruptcy "we're done"?

Is no accountability for affiyasassa revenue as promised come to a "we're done"?

Is it a "We're done" after shareholders sitting at a 90% loss on their Investment in XCRT?

As the old saying goes Is Mike just going to S@#% and walk away?


IMO

Blah, blah, blah….

Pre Xcelerate??

I know/known a bunch of professionals that do great work in their fields. Most all have had an issue or two. It comes with the territory.

Get a life already!

Holy Smokes how did I miss that?

Michael O'Shea a part time CEO failing on his other promises as well as XCRT?

Now this is solid DD, bravo!

Shoddy O'Shea?

IMO

S/S Unchanged. No dilution continues!

https://www.otcmarkets.com/stock/XCRT/security

Wow the pot calling the proverbial kettle black!

Just as you folks have been saying for several years now that XCRT is the real deal .... you better load up ... better stock up right now 'cause it's gonna be skyrocketing ... and yet the pps slowly slowly drops this whole time

... and yet again Michael O'shea lied for the seventh time when he clearly stated that there would be revenue starting in the fourth quarter of 2024 from Africa operations

before you criticize the little piece of wood in someone else's eye, better get the big piece of wood out of your own.

And please no childish rationalizations such as the accounting issue, as if an administrative hassle would prevent a multi million dollar investment that has been forecast continually for 3 years .... michael O'shea has been lying about Africa ... What else is he lying about?

And of course since you fellows do such good DD you must know that O'shea has been very busy in recent times with his forensic accounting! He hasn't been a full time CEO by any means of XCRT ..... in a recent court case, the court took O'shea to the woodshed calling his forensic accounting shoddy ... he was forced into a deposition to discuss an egregious oversight on his part In his analysis of a major insurance fraud ..... The purpose of the deposition was to find out if O'shea had colluded with the perpetrator of the fraud, since his shoddy work seemed to be protecting one of the parties accused of fraud

Why don't you guys go find this case? .... it's publicly available and you guys do such good dd

what Pompous morons on the OTC!

Holy cow you’ve been saying that for over a year! Wrong! Go Xcrt!

We know who the pumping clowns really are. All one has to do is look at posting history. 

Next up Sub Penny? Is that in the filings?

From .174 to .013?

Do they address that?

Bozo 3rd party clowns pumping trash and assumptions from .13 to .013 do they account for that?

Imagine pumping this crap at .10 then coming back to bragging about your position?

Or how much money you've made on the toxic death spiral the PPS went?

Great stuff?


IMO

Damn you’re dense! Read the first entry under “Revenues”. Revenue of $1,122,085 were recorded for Xcelerate as of Dec 31, 2023. It has nothing to do with the “boiler plate” verbiage in the filing. Wow🤠

2024 revenues will no doubt far exceed 2023’s.

Joe P has never been in the loop fool. That was a dig on the stupidity of any ever thinking he was. Geese. Read the filings instead of plastering gibberish all over this thread. PLEASE!!!

Revenues

Total Revenue 1,122

https://www.otcmarkets.com/stock/XCRT/financials

" The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements./i]"

Everything these hack promoters regurgitate is an assumption?

From .13 to .013 nothing but assumptions?

When you call them out on their assumptions they copy and paste literally someone telling you it's an assumption?

Do they ever do there own DD?

PS Joe died, which might be why no one has heard anything from Xcelerate or Mike, he's gone darker than the Hawk Tuah girl?

Where in the world is Mikey Oshandiego?

IMO

Cost of product, delivery, advertising, services, fees, service charges, losses of product, employees…on and on and on, are all why a company also has account fees.

A lot goes into running a company - more so when you have subsidiaries under your umbrella - a little like Xcelerate. IMO

Hmm, why would “the acquisition of ESN” be in the most recent filing of an Xcelerate 1-SA SEC Filing? Weird IMO

Dammit, maybe I should read more about Xcelerate instead of throwing chit on the wall to see if I get attention….naw, sounds too much like actual work. IMO


Start of page 14:


[The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements. The most significant estimates relate to the calculation of stock-based compensation, accounting for the ASA transaction, accounting for the acquisition of the ESN, income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these condensed financial statements./i]

Let’s assume no one really gives a chit what “your opinion” “is” about Xcelerate and/or anything XCRT related and go from there to your BIO page instead. IMO
😉😉😉

Where the hell is ole Joey boy? No Kidding? Must of skipped out on the ole Official Documents that companies have to file to stay current with the SEC. IMO

Not a Joke Man!

Starting on page 42:

[MANAGEMENT

Directors and Executive Officers

The following table and biographical summaries set forth information, including principal occupation and business experience about our directors, director nominees and executive officers:

Name Position Age Director or Officer Since
Michael F. O’Shea Chief Executive Officer, Director 73 2020
Jason Householder Director 40 2020
Steve Gravely Director 72 2020
Jon Wilken Director 73 2022
Dr. Anja Glisovic Interim Chief Science Officer 45 2020

Michael F. O’Shea-CEO, President, Director, & Chairman. Mr. O’Shea was appointed as our Chief Executive Officer and as a director in May 2020. He is a forensic accountant and a licensed private investigator. Since 1999, Mr. O’Shea has been the Director of Forensic Research Group, Inc. and has been responsible for implementing and supervising its forensic accounting, financial investigation, and corporate due diligence programs. He has worked closely with such agencies as the Federal Deposit Insurance Corporation, Resolution Trust Corporation, FBI, Office of the Controller of the Currency, US Secret Service and ATF. He has been admitted, on numerous occasions, as an expert witness in forensic accounting in both Federal and State court as well as foreign jurisdictions. He has on several occasions been appointed as a Receiver by the State Court in South Carolina and Florida. From 1985-1998 he served as Director of Investigations for Investigative Research Group, Inc., a firm that specialized in corporate due diligence, asset searches, bankruptcy review, and loan recovery. He has been devoting a majority of his time to our affairs and expects to devote a significant amount of his time to our business following this offering.

Steve Gravely-Director. Steve Gravely was appointed as a director in July 2020. Since 2003 he has been President of the Consulting Group of Jocassee, Inc. He has been responsible for the start-up of 25 manufacturing plants around the world and over 300 new product introductions for large corporations such as Michelin, AT&T, NCR, Fluor/Maruti (India), and Fluor/General Motors. Mr. Gravely’s other prior business experience includes holding the positions of the R&D Computer Systems Integration Manager for NCR in the testing and design development of new PC's and the Director of Operations for AT&T’s Global Information Solutions (NCR) for both North American and South America, where he was responsible for the operation of manufacturing facilities in Brazil, California, and South Carolina. He graduated from Clemson University with a BS in Industrial Engineering in 1973. He devotes only such time as necessary to our affairs.

Jason Householder–Director. Jason Householder was appointed as a director in December 2020. In May 2018, he co-founded and has been CEO of Charlotte based LenDRgroup Consulting, a company providing financing to dentists, physicians, and veterinarians in South Carolina. In addition, since 20__ he has been the Manager of House Holdings LLC,, Charlotte, SC, a business consulting firm. He has over 15 years’ experience in the healthcare and banking sectors and specializes in assisting medical, dental, and veterinary practices to devise strategies that to run their businesses effectively and achieve peak performance.. He devotes only such time as necessary to our affairs.

Jon Wilken – Director. Mr. Wilken was appointed as a director in May 2022. In addition to his position as a director of our Company, since 2008 he has been President and CEO of HS Pharmaceuticals, a company engaged in oncology research and the development of human and animal health care and medical products, as well as cosmetics and beauty products. Prior to founding HS Pharmaceuticals, Mr. Wilken was President and CEO of BILO Inc., a supermarket chain which at the time of his employment was wholly owned by Ahold NV of The Netherlands. During his tenure the company employed approximately 26,000 people and operated over 400 retail supermarkets and convenience stores in four Southeastern States with annual sales of approximately $4 Billion.

Dr. Anja Glisovic-Rösch (née Glisovic)-Interim Chief Science Officer. Dr. Glisovic-Rösch was appointed as our Chief Science Officer in September 2020. Since 2008, she has been R&D Project Leader for the Fraunhofer Institute, one of the world’s leading applied research organizations. She holds numerous patents in the fields of medical devices, chemical engineering, and small arms and munitions. Dr. Glisovic received her PhD in X-Ray and Material Physics from Germany’s Georg-August Universität in 2007. She devotes only such time as necessary to our affairs.


42


Director Nominees. Upon effectiveness of this offering the following persons have agreed to being appointed as directors of our Company. Except for Mr. O’Shea, who will remain in his current positions, the current directors have agreed to resign.

Katherine Beebe DeVarney, Ph.D, will be appointed as a director of our Company on the effective date of this prospectus. Since 2007 Dr. DeVarney has been employed by Titan Pharmaceuticals Inc. (NASDAQ: TTNP), a US pharmaceutical company. She originally joined Titan in February 2007 and currently serves as its President and Chief Operating Officer. She has been a member of the Titan Board since December 2019 and is also on the Board of BioCorRx Pharmaceuticals. During her 17 years with Titan, she served in various senior executive, scientific and medical research and development capacities, with primary responsibility for oversight of product research and development, Regulatory Affairs, and Medical Affairs. Dr. DeVarney has 28 years of experience as a Neuroscientist in the pharmaceutical industry, including positions of increasing responsibility with SmithKline Beecham, GlaxoSmithKline, Merck, and Corcept Therapeutics. Prior to her pharmaceutical career, Dr. DeVarney was a hospital-based clinician and worked in academic medicine for 10 years. She received her Ph.D. in Clinical Neuropsychology from George Mason University and completed a two-year post-doctoral fellowship at Graduate Hospital and the University of Pennsylvania. Based on Dr. DeVarney’s extensive knowledge of the medical, research, and regulatory requirements of product development programs, our Board believes that Dr. DeVarney has the appropriate set of skills to serve as member of the Board.

Jervis Hough, will be appointed as a director of our Company on the effective date of this prospectus. Mr. Hough has been a brokerage professional with over twenty (20) years of proven analytical, interpretive, and communication skills in the securities industry. Since 2018 he has been employed as the Chief Compliance Officer/Chief Operating Officer/Senior Vice President of Blaylock Van, LLC, Atlanta, GA and New York. He has also been employed as a compliance examiner at FINRA, District 7, Atlanta, GA. Mr. Hough holds numerous securities licenses, including Series 7, 24, 53, 63, 79 and 99. He is a Certified Securities Compliance Professional® (National Society of Compliance Professionals) and a past associate member of the Association of Certified Fraud Examiners. Mr. Hough received an MS degree in Applied Economics from Clemson University in 2000 and a BS degree in Economics from Clemson University, John E. Walker School of Economics in 1997. Mr. Hough currently serves on the Board of Directors and Chair of the Audit Committee of Progressive Care Inc. (OTC:RXMD) and has been a Board member since August 2017. Based on Mr. Hough’s extensive experience in the securities industry and general business knowledge our Board believes that he has the appropriate set of skills to serve as member of the Board.

David Natan will be appointed as a director of our Company on the effective date of this prospectus. He will also assume the position as Chairperson of our Audit Committee of the Board. He currently serves as CEO of Natan & Associates, LLC, a consulting firm offering CFO services to public and private companies since 2007. From February 2010 to May 2020, Mr. Natan served as CEO of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on LED lighting products. From February 2002 to November 2007, Mr. Natan served as CFO of PharmaNet Development Group, Inc., a drug development company, and, from June 1995 to February 2002, as CFO and VP of Global Technovations, Inc., a manufacturer and marketer of speaker components. Prior to that, Mr. Natan served in various roles with Deloitte & Touche LLP. From April 2020 through June 2023, Mr. Natan was Executive Vice President and Chief Financial Officer for Airborne Motorworks, Inc., Spokane, WA, a privately-held aerospace transportation company. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of NetBrands, Inc. (OTC: NBND), a distributor of snack products, since February 2021; and Sunshine Biopharma Inc., (NASDAQ: SBFM), a Canadian pharmaceutical company. Additionally, in November 2023, Mr. Natan was appointed to the board of Directors and Audit Committee Chair of Minim Inc. (NASDAQ: MINM). Mr. Natan also has served as Audit Chair of Opgen Inc. a biotech company (Nasdaq :GPGN) since March 2024. Mr. Natan holds a B.A. in Economics from Boston University. Mr. Natan’s experience as a business executive and as a director and chairperson of audit committees for public companies qualifies him to serve on our board of directors.

Doyle B. Word will be appointed a director of our Company on the effective date of this prospectus. Since December 2021, he has been a co-manager of one of our current subsidiaries, Afyi Sasa Africa LLC. In addition, beginning in 2008 he began working with Madaktari Africa LLC, a non-profit corporation that partnered with major universities to teach neurosurgery and other medical procedures in Tanzania, where he was a member of the Board of Directors from December 2019 to the present, Chief Executive Officer from 2008 to 2014 and Director of Finance from January 2020 to the present. He graduated from Auburn University with a Bachelor of Science degree in Industrial Engineering. Based on Mr. Word’s extensive experience and knowledge of expanding medical treatment in Africa, our Board believes that he has the appropriate set of skills to serve as member of the Board.

Board of Directors

We have no formal policy regarding board diversity. In selecting board candidates, we seek individuals who will further the interests of our stockholders through an established record of professional accomplishment, the ability to contribute positively to our collaborative culture, knowledge of our business and understanding of our prospective markets.
/i]

https://www.otcmarkets.com/filing/html?id=17716303&guid=oL0-k6F-MgwfJth

Why the hell would I do this if there was no compensation for my efforts? Nobody works for free these days. Including folks that spend an inordinate amount of time time trashing inter web bulletin boards IMO

Starting at the bottom of page 12:

[The aggregate cost of these acquisitions was $456,312. The Company funded the acquisition through a $400,000 interest-free loan from an unaffiliated person, as well interest-free loans from the Company’s CEO. The Company issued 3,000,000 shares of its common stock in consideration for the $400,000 loan. The ESN Group of companies offer Earth Science® nature-inspired beauty and personal care products and Ceramedx® therapeutic skincare solutions. The offered products are paraben-free, cruelty-free products with ingredients that include plant-based nutrients and antioxidants, soothing botanicals, hydrating moisturizers and pure essential oils.

As part of these transactions, the Company retained the services of John Jay Kline, the former President of the ESN Group of companies, who has continued to operate both companies on the Company’s behalf. As part of the consideration for his employment, in July 2023 the Company agreed to issue him 2,000,000 shares of common stock. These shares were valued at $0.1170 each, or a total of $234,000.

The Company’s year-end is December 31./i]

https://www.otcmarkets.com/filing/html?id=17852428&guid=oL0-k6F-MgwfJth

[Comparison of Results of Operations for the Years Ended December 31, 2023 and 2022

Revenue was $1,122,085 for the year ended December 31, 2023, due to the inclusion of five months of revenue from the ESN Group, compared to $-0- during the year ended December 31, 2022./i]

Page 31…. Read

https://www.otcmarkets.com/filing/html?id=17716303&guid=oL0-k6F-MgwfJth

Xcelerate doesn't own the companies who produce the product?

They acquires a percentage, which no one knows what it is?

Let's assume 51%?

The company who produces the product gets the product cost back to them, then I assume you have to deduct advertising and distribution costs, then what % does XCRT walk away with?

You're acting like Xcelerate is receiving all the income from a company they don't own they only took interest in?

Let's clear up what majority interest is vs. Majority ownership?

You've been assuming Xcelerate will generate revenue but haven't produced a shred of evidence they have?

You only believe they will?

That's dangling the carrot? And not solid facts investors can bank on?

This fallacy of revenue has been regurgitated for awhile now and all the thought has produced is no revenue and a 90% decrease in PPS?

You can claim anything you want but what happens if the claims continue to Xcelerate files chapter 13 bankruptcy?

I guess in the aspect people will fantasize about the reconstruction of the shell after bankruptcy?


IMO

Communication is lacking currently…but XCRT isn’t your typical pump n dump ticker either! IMO


Very

I do my best to avoid negativity and losers on social media talkie forums. A little DD actually goes a long way! iMO

Xcelerate is a non-diluting, growing in revenue start-up…typically it takes 4-5 years before any potential for even meager profits to become realized. And profits may very well be just around the corner. Plenty of time…only getting started. IMO

VERY

Folks are gonna be surprised at future revenues. IMHO

Ceramedx and Earth Science products are showing up everywhere. Doesn’t Xcelerate have a majority stake in the ESN Group/Earth Science product line? Wasn’t the ESN Group the only reason we saw dilution a couple years back? IMO

https://www.otcmarkets.com/otcapi/company/dns/news/document/68267/content

No dilution since?

Read - explains “Restricted” diluted shares and what they were used for:

https://www.otcmarkets.com/stock/XCRT/news/Xcelerate-Inc-Announces-Agreement-to-Acquire-a-Controlling-Interest-in-ESN-Inc?id=396386

ESN Group/associated products are already worth more than current market cap! IMHO

Products are EVERYWHERE now! Hells Bellz, Ceramedx is even stocked on the shelf of my local Safeway Grocery? I don’t live in a big city either. LMFAO!!!

Great reviews!

https://www.safewayus.com/product/ceramedx-facial-lotion-soothing-1-each-4-fz/

https://www.amazon.com/ceramedx-restoring-body-lotion-unscented/dp/b07hbhbnfj

https://www.walmart.com/search/?query=products+with+ceramides&&adid=22222222225417210781&wmlspartner=wmtlabs&wl0=p&wl1=o&wl2=m&wl3=72636889731676&wl4=kwd-72637322211175:loc-190&wl5=111369&wl6=&wl7=&wl14=walmart%20online%20ceramedx&veh=sem&msclkid=d2e8c7547e0f157d4354a0c0215cbfe5

https://www.target.com/b/ceramedx/-/N-q643lenwhes

Earth Science:

https://earthsciencebeauty.com/



Everywhere I tell ya!!!

Very

How could a CEO fail this badly?

Years ago I stated I believed Michael O'Shea was a patsy is a bigger pyramid scheme?

But who is really controlling or nose diving this shell into the ground?

Is Mike that incompetent? Or is there something far more nefarious going on here?

.13 to .014?

Bernie Maddoff ran better numbers than this?

Very rarely do i get to watch a complete meltdowns by a company this quickly?

It's amazing?

IMO

I'm curious as to what the deflections are? This is an OTC stock. Toxic spirals are more like TOMDF types of stock. That was pumped into oblivion. Curious if anyone on this board pumped that stock while it was churning out shares by the billions.

Anyone have any idea who pumped that stock? 

Just like the Graf Zeppelin !

No dilution for well over a year now. Not typical in OTC land.

Sitting @ ~ $6 Market Cap? The skin care product line is doing very good - worth well over current Market Cap all by itself. Non-dilutive loan? Next quarterly will reflect revenue growth Y/Y by leaps and bounds. Share price is stupid cheap.

A little update from management and this will fly.

https://www.otcmarkets.com/stock/XCRT/security

Anyone else notice the sharp decline in PPS since Joe Pignatiello died?

I wonder if he had more to do with XCRT than first anticipated?

It seems nothing can fix this toxic spiral the PPS has entered in too?

Sad day for shareholders?

Sad year for shareholders?

They believed in Michael O'Shea so much?

IMO

.0141 new lows as con artist try to deflect?

Disgusting?

That 50 million shares Mike diluted won't hold him over forever?

It's getting ugly?

Most of the 3rd party con artist defending Mike scattered like roaches?

You simply can't justify .174 to .014?

Don't try?


IMO

I thought pyramid schemes had dilution of shares? 

Oh wait that was the one that some people were touting a ways back.

I think it was TOMDF.

Apparently neither do pyramid schemes?

IMO

Penny stocks don't shock anyone anymore.

Supporters in a state of verbal shock !
$0.174 est 2021.

.0174? Why does that PPS seem so familiar?


Great Job Mike?

.174 to .0174?

Hows retirement?

IMO

Magic Mike Oshea?

How else can you explain .174 to .0174?

Magician?

IMO

This is like a financial whirlpool !

Seems the 3rd party con artist who promoted the Titanic success of XCRT from .13 to .0168 have all but vanished?

There are a few crying about other stocks but the XCRT crowd seems to have moved on?

Wish we could go back in time when all these promoters family members were rubbing caremedX all over themselves with glee that XCRT took a percentage in a skin care line?

Does anyone know what the exact % was?

They screamed about profits but if they only acquired a certain percentage obviously those profits are only a fraction as they have to be split?

Good old Wendy-bullz all over X making up hypethiticals with her 14 followers about Mike and XCRT?

But the one memory we have that we can all reminiscing about was Dr Dilan Ellagala and the fantasies of affiyasassa?

Anyone remember that? Seems to have just passed on like Joe Pignatiello the Sales director at XCRT?

No one of the minimal promoters who even show up on social media anymore even talk about it?

Did it ever happen? I bet no one would like the answer when they contact dilan?

They won't?

Ever?

IMO

I find so much irony when posts get deleted.

Truth hurts. Does it not?

Can dish it out but can't take it.

Oh the irony in 3rd party bashing. 

Correction** .174 to .0167 that's what they call leadership from a CEO?

No phony well worded PR that's twisted by some slimy 3rd party hack promoter will ever justify what Michael O'Shea has actually done to XCRT investors?

Link in the sticky notes?

IMO

Wait until XCRT hit .008 and these bottom feeding 3rd party dump and dump promoters start telling everyone "thank goodness I bought in the trips"?

Can't wait?

They could pour that slop all over social media?

IMO